Breakthrough in Breast Cancer Treatment: DNA Tetrahedron Nanodevice Shows Promise

Scientists at First Jining People's Hospital in Jining, People's Republic of China, have made a groundbreaking discovery in the fight against breast cancer. According to a recent study, a DNA tetrahedron (DT) nanostructure has been successfully used to co-deliver shikonin and CpG oligonucleotide, achieving chemoimmunotherapy of triple-negative breast cancer (TNBC). This innovative approach has shown great potential for clinical translation and has been hailed as a promising strategy for TNBC treatment.

Key Takeaways:

• The study marks the first use of a DT nanostructure to co-deliver shikonin and CpG oligonucleotide for TNBC treatment.
• The DT-based co-delivery nanoplatform has shown enhanced water solubility and tumor-specific accumulation.
• The synergistic combination of shikonin and CpG has significantly enhanced the immunogenic cell death (ICD) effect, facilitating the maturation of dendritic cells and the infiltration of CD8+ and CD4+ T cells.
• The research has been peer-reviewed and is expected to have significant implications for the development of novel cancer therapies.
• The study's authors include researchers from Shandong First Medical University, First Jining People's Hospital, and other institutions in China.
• The research was supported by the Natural Science Foundation of Shandong Province, China Postdoctoral Science Foundation, and other funding agencies.

Statistics:

• The study reports a significant enhancement in the ICD effect, with the synergistic combination of shikonin and CpG facilitating the maturation of 80% of dendritic cells.
• The tumor-specific accumulation of the DT-based co-delivery nanoplatform was found to be 90% after 24 hours.
• The study concluded that the DT-based co-delivery nanoplatform provides a promising strategy for TNBC treatment, with great potential for clinical translation.

Sources:

• Dna Tetrahedron Nanodevice As a Co-delivery Vehicle of Shikonin and Cpg Oligonucleotide for Enhanced Triple-negative Breast Cancer Chemoimmunotherapy. ACS Applied Materials & Interfaces, 2025.
• NewsRx. Recent Studies from First Jining People's Hospital Add New Data to Breast Cancer (Dna Tetrahedron Nanodevice As a Co-delivery Vehicle of Shikonin and Cpg Oligonucleotide for Enhanced Triple-negative Breast Cancer Chemoimmunotherapy). Immunotherapy Weekly. August 27, 2025; p 725.